Moreover, safety and long-term tolerability of anti-VEGF-A therapy in SpA patients remain an important consideration, as the use of anti-VEGF-A mAbs may cause systemic adverse effects, including hypertension, proteinuria, and risk of thromboembolic events seen in cancer patients [55, 56]. Here, VEGFA is linked to hypertensive disorder.